STAT+: A journey to witness China’s biotech boom up close

AI Summary

STAT reports from Shanghai on China’s expanding biotechnology sector, where Chinese-designed drugs make up roughly half of the global drug-development pipeline. The growing competition is prompting concern among U.S. industry observers.

Chinese-designed drugs now account for roughly half the global pipeline. STAT's Jason Mast traveled to Shanghai to get an up-close look at the competition that's making American's nervous.